Document Detail

Long-term treatment of alpha1-antitrypsin deficiency-related pulmonary emphysema with human alpha1-antitrypsin. Wissenschaftliche Arbeitsgemeinschaft zur Therapie von Lungenerkrankungen (WATL)-alpha1-AT-study group.
MedLine Citation:
PMID:  9551749     Owner:  NLM     Status:  MEDLINE    
Alpha1-antitrypsin (alpha1-AT) deficiency is a genetic disorder characterized by low serum levels of alpha1-AT and a high risk of pulmonary emphysema at a young age. The resulting surplus of proteases, mainly of neutrophil elastase, can be balanced by i.v. augmentation with alpha1-AT. However, it is not clear if affected patients benefit from long-term augmentation therapy and no long-term safety data are available. We examined 443 patients with severe alpha1-AT deficiency and pulmonary emphysema receiving weekly i.v. infusions of 60 mg x kg body weight(-1) alpha1-AT in addition to their regular medication. The progression of the disease was assessed by repeated lung function measurements, particularly the decline in forced expiratory volume in one second (deltaFEV1). Four hundred and forty three patients with alpha1-AT deficiency tolerated augmentation therapy well with few adverse reactions. The deltaFEV1 in 287 patients with available follow-up data was 57.1+/-31.1 mL x yr(-1). Stratified for baseline FEV1, the decline was 35.6+/-21.3 mL in the 108 patients with an initial FEV1 <30% and 64.0+/-26.4 mL in the 164 with FEV1 30-65% of predicted normal (p=0.0008). The remaining 15 patients had an initial FEV1 >65% pred. Long-term treatment with i.v. alpha1-antitrypsin in patients with severe alpha1-antitrypsin deficiency is feasible and safe. The decline in forced expiratory volume in one second is related to the initial forced expiratory volume in one second as in alpha1-antitrypsin deficient patients not receiving augmentation therapy.
M Wencker; N Banik; R Buhl; R Seidel; N Konietzko
Related Documents :
15166619 - Acute lung injury as an adverse event of gefitinib.
7874809 - Scintigraphic appearances in patients with pulmonary infection and lung scintigrams of ...
1440469 - Pulmonary kaposi's sarcoma in africa.
9424399 - Pulmonary lymphangioleiomyomatosis: prolonged survival despite multiple pregnancies and...
18454219 - Dyspnea, pulmonary function and exercise capacity in adult saudi patients with sickle c...
9924639 - Airway responsiveness to inhaled albuterol in patients with pulmonary hypertension.
23095259 - Long-term treatment of lewis-sumner syndrome with subcutaneous immunoglobulin infusions.
1268769 - Direct leukocyte migration inhibition in multiple sclerosis--a possible assessment of a...
20032909 - Evaluation of a patient-specific index as an outcome measure for physiotherapy in parki...
Publication Detail:
Type:  Clinical Trial; Journal Article; Multicenter Study    
Journal Detail:
Title:  The European respiratory journal     Volume:  11     ISSN:  0903-1936     ISO Abbreviation:  Eur. Respir. J.     Publication Date:  1998 Feb 
Date Detail:
Created Date:  1998-06-12     Completed Date:  1998-06-12     Revised Date:  2013-05-23    
Medline Journal Info:
Nlm Unique ID:  8803460     Medline TA:  Eur Respir J     Country:  DENMARK    
Other Details:
Languages:  eng     Pagination:  428-33     Citation Subset:  IM    
Ruhrlandklinik, University Hospital, Essen, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Feasibility Studies
Forced Expiratory Volume / physiology
Injections, Intravenous
Longitudinal Studies
Middle Aged
Prospective Studies
Pulmonary Emphysema / drug therapy*,  etiology*,  physiopathology
Time Factors
alpha 1-Antitrypsin / adverse effects,  therapeutic use*
alpha 1-Antitrypsin Deficiency / complications*
Reg. No./Substance:
0/alpha 1-Antitrypsin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Effects of proportional assist ventilation on exercise tolerance in COPD patients with chronic hyper...
Next Document:  Heart block in patients with obstructive sleep apnoea: pathogenetic factors and effects of treatment...